<li>aceclofenac<p>heparin and aceclofenac both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>acemetacin<p>heparin and acemetacin both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>agrimony<p>heparin and agrimony both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>alfalfa<p>heparin and alfalfa both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>alteplase<p>heparin and alteplase both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>american ginseng<p>heparin and american ginseng both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>anamu<p>heparin and anamu both increase  anticoagulation. Use Caution/Monitor.</p></li><li>antithrombin iii<p>antithrombin iii increases effects of heparin by pharmacodynamic synergism. Use Caution/Monitor. Use reduced dose of heparin during antithrombin III therapy to avoid bleeding.</p></li><li>aspirin<p>heparin and aspirin both increase  anticoagulation. Modify Therapy/Monitor Closely.<span><br><br></span>aspirin, heparin.
Either increases toxicity of the other by anticoagulation. Use Caution/Monitor. The need for simultaneous use of low-dose aspirin and anticoagulant or antiplatelet agents are common for patients with cardiovascular disease; monitor closely.</p></li><li>aspirin rectal<p>heparin and aspirin rectal both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>aspirin/citric acid/sodium bicarbonate<p>aspirin/citric acid/sodium bicarbonate, heparin.
Either increases toxicity of the other by anticoagulation. Use Caution/Monitor. The need for simultaneous use of low-dose aspirin and anticoagulant or antiplatelet agents are common for patients with cardiovascular disease; monitor closely.<span><br><br></span>heparin and aspirin/citric acid/sodium bicarbonate both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>azapropazone<p>azapropazone increases effects of heparin by plasma protein binding competition. Use Caution/Monitor.</p></li><li>azathioprine<p>azathioprine decreases effects of heparin by unknown mechanism. Use Caution/Monitor.</p></li><li>azficel-t<p>azficel-t, heparin. Other (see comment). Use Caution/Monitor. 
Comment: Coadministration with anticoagulants or antiplatelets may increase bruising or bleeding at biopsy and/or injection sites; concomitant use not recommended. Decisions regarding continued use or cessation of anticoagulants or antiplatelets should be made by a physician.</p></li><li>azilsartan<p>heparin increases toxicity of azilsartan by Other (see comment). Use Caution/Monitor. 
Comment: Low molecular weight heparins may suppress adrenal aldosterone secretion, which can potentially cause hyperkalemia.</p></li><li>benazepril<p>heparin increases toxicity of benazepril by Other (see comment). Use Caution/Monitor. 
Comment: Low molecular weight heparins may suppress adrenal aldosterone secretion, which can potentially cause hyperkalemia.</p></li><li>budesonide<p>budesonide, heparin. Other (see comment). Use Caution/Monitor. 
Comment: Corticosteroids may decrease anticoagulant effects by increasing blood coagulability; conversely, they may impair vascular integrity, thus increasing bleeding risk.  Monitor INR closely.</p></li><li>canagliflozin<p>heparin and canagliflozin both increase  serum potassium. Use Caution/Monitor.</p></li><li>candesartan<p>heparin increases toxicity of candesartan by Other (see comment). Use Caution/Monitor. 
Comment: Low molecular weight heparins may suppress adrenal aldosterone secretion, which can potentially cause hyperkalemia.</p></li><li>capecitabine<p>capecitabine increases effects of heparin by unspecified interaction mechanism. Use Caution/Monitor.</p></li><li>captopril<p>heparin increases toxicity of captopril by Other (see comment). Use Caution/Monitor. 
Comment: Low molecular weight heparins may suppress adrenal aldosterone secretion, which can potentially cause hyperkalemia.</p></li><li>carbamazepine<p>carbamazepine decreases levels of heparin by increasing metabolism. Use Caution/Monitor.</p></li><li>celecoxib<p>heparin and celecoxib both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>chitosan<p>chitosan increases effects of heparin by Other (see comment). Use Caution/Monitor. 
Comment: Chitosan can decrease GI absorption of vitamin K, enhancing anticoagulant effects.</p></li><li>choline magnesium trisalicylate<p>heparin and choline magnesium trisalicylate both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>cinnamon<p>heparin and cinnamon both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>citalopram<p>citalopram increases effects of heparin by pharmacodynamic synergism. Use Caution/Monitor. Combination may increase risk of bleeding.</p></li><li>clobetasone<p>clobetasone, heparin. Other (see comment). Use Caution/Monitor. 
Comment: Corticosteroids may decrease anticoagulant effects by increasing blood coagulability; conversely, they may impair vascular integrity, thus increasing bleeding risk.  Monitor INR closely.</p></li><li>clopidogrel<p>heparin, clopidogrel.
Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Enhanced risk of hemorrhage; additive effects are intended when both drugs are prescribed as indicated for ACS.</p></li><li>collagenase clostridium histolyticum<p>heparin increases toxicity of collagenase clostridium histolyticum by anticoagulation. Use Caution/Monitor. Collagenase clostridium histolyticum has high incidence of ecchymosis/contusion at injection site; avoid concomitant anticoagulants (except for low-dose aspirin, ie, up to 150 mg/day).</p></li><li>conjugated estrogens, vaginal<p>conjugated estrogens, vaginal decreases effects of heparin by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Risk of thromboembolic disorders.</p></li><li>cordyceps<p>heparin and cordyceps both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>cornsilk<p>cornsilk decreases effects of heparin by pharmacodynamic antagonism. Use Caution/Monitor. Cornsilk contains vitamin K; consume a consistent amount daily.</p></li><li>cortisone<p>cortisone, heparin. Other (see comment). Use Caution/Monitor. 
Comment: Corticosteroids may decrease anticoagulant effects by increasing blood coagulability; conversely, they may impair vascular integrity, thus increasing bleeding risk.  Monitor INR closely.</p></li><li>cyclophosphamide<p>cyclophosphamide increases effects of heparin by unknown mechanism. Use Caution/Monitor. Due to potential thrombocytopenic effects of cyclophosphamide, an additive risk of bleeding may be seen in patients receiving concomitant anticoagulants.</p></li><li>danshen<p>heparin and danshen both increase  anticoagulation. Use Caution/Monitor.</p></li><li>deferasirox<p>deferasirox, heparin. Other (see comment). Use Caution/Monitor. 
Comment: Gastric ulceration and GI bleeding have been reported in patients taking deferasirox, use caution when coadministering with other drugs known to increase the risk of peptic ulcers or gastric hemorrhage including anticoagulants.</p></li><li>deflazacort<p>deflazacort, heparin. Other (see comment). Use Caution/Monitor. 
Comment: Corticosteroids may decrease anticoagulant effects by increasing blood coagulability; conversely, they may impair vascular integrity, thus increasing bleeding risk.  Monitor INR closely.</p></li><li>devil's claw<p>heparin and devil's claw both increase  anticoagulation. Use Caution/Monitor.</p></li><li>dexamethasone<p>dexamethasone, heparin. Other (see comment). Use Caution/Monitor. 
Comment: Corticosteroids may decrease anticoagulant effects by increasing blood coagulability; conversely, they may impair vascular integrity, thus increasing bleeding risk.  Monitor INR closely.</p></li><li>diclofenac<p>heparin and diclofenac both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>diflunisal<p>heparin and diflunisal both increase  anticoagulation. Modify Therapy/Monitor Closely.<span><br><br></span>diflunisal increases effects of heparin by plasma protein binding competition. Use Caution/Monitor.</p></li><li>dong quai<p>heparin and dong quai both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>enalapril<p>heparin increases toxicity of enalapril by Other (see comment). Use Caution/Monitor. 
Comment: Low molecular weight heparins may suppress adrenal aldosterone secretion, which can potentially cause hyperkalemia.</p></li><li>epoprostenol<p>heparin and epoprostenol both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>eprosartan<p>heparin increases toxicity of eprosartan by Other (see comment). Use Caution/Monitor. 
Comment: Low molecular weight heparins may suppress adrenal aldosterone secretion, which can potentially cause hyperkalemia.</p></li><li>ethanol<p>ethanol increases effects of heparin by unknown mechanism. Use Caution/Monitor. Acute EtOH intoxication.</p></li><li>ethotoin<p>heparin increases levels of ethotoin by unknown mechanism. Use Caution/Monitor.<span><br><br></span>ethotoin, heparin. Other (see comment). Use Caution/Monitor. 
Comment: Hydantoin anticonvulsants increase anticoagulant effects at first, then decrease those effects with continued use (2+ wks).  There are multiple mechanisms involved, including enzyme induction, plasma protein binding site competition, and additive effects on prothrombin time.</p></li><li>etodolac<p>heparin and etodolac both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>etoricoxib<p>heparin and etoricoxib both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>fenbufen<p>heparin and fenbufen both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>fennel<p>heparin and fennel both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>fenoprofen<p>heparin and fenoprofen both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>feverfew<p>heparin and feverfew both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>fish oil<p>fish oil, heparin. Other (see comment). Use Caution/Monitor. 
Comment: Patients taking fish oil and an anticoagulant or other drug affecting coagulation should be monitored periodically due to potential increased risk of bleeding. .</p></li><li>fludrocortisone<p>fludrocortisone, heparin. Other (see comment). Use Caution/Monitor. 
Comment: Corticosteroids may decrease anticoagulant effects by increasing blood coagulability; conversely, they may impair vascular integrity, thus increasing bleeding risk.  Monitor INR closely.</p></li><li>fluorouracil<p>fluorouracil increases effects of heparin by unspecified interaction mechanism. Use Caution/Monitor. Due to the thrombocytopenic effects of fluorouracil, an additive risk of bleeding may be seen in patients receiving concomitant anticoagulants.</p></li><li>flurbiprofen<p>heparin and flurbiprofen both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>forskolin<p>heparin and forskolin both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>fosinopril<p>heparin increases toxicity of fosinopril by Other (see comment). Use Caution/Monitor. 
Comment: Low molecular weight heparins may suppress adrenal aldosterone secretion, which can potentially cause hyperkalemia.</p></li><li>fosphenytoin<p>heparin increases levels of fosphenytoin by unknown mechanism. Use Caution/Monitor.<span><br><br></span>fosphenytoin, heparin. Other (see comment). Use Caution/Monitor. 
Comment: Hydantoin anticonvulsants increase anticoagulant effects at first, then decrease those effects with continued use (2+ wks).  There are multiple mechanisms involved, including enzyme induction, plasma protein binding site competition, and additive effects on prothrombin time.</p></li><li>garlic<p>heparin and garlic both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>gemcitabine<p>gemcitabine increases effects of heparin by unspecified interaction mechanism. Use Caution/Monitor. Due to the thrombocytopenic effects of gemcitabine, an additive risk of bleeding may be seen in patients receiving concomitant anticoagulants.</p></li><li>ginger<p>heparin and ginger both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>ginkgo biloba<p>heparin and ginkgo biloba both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>glucagon<p>glucagon increases effects of heparin by unknown mechanism. Use Caution/Monitor.</p></li><li>green tea<p>green tea, heparin. Other (see comment). Use Caution/Monitor. 
Comment: Combination may increase risk of bleeding, caution is advised.</p></li><li>hemin<p>heparin, hemin.
Either increases effects of the other by anticoagulation. Use Caution/Monitor. Hemin degradation product (ie, hematin) may produce coagulopathy (eg, thrombocytopenia, platelet degranulation) and cause mild anticoagulant effects.</p></li><li>horse chestnut seed<p>heparin and horse chestnut seed both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>hydrocortisone<p>hydrocortisone, heparin. Other (see comment). Use Caution/Monitor. 
Comment: Corticosteroids may decrease anticoagulant effects by increasing blood coagulability; conversely, they may impair vascular integrity, thus increasing bleeding risk.  Monitor INR closely.</p></li><li>ibuprofen<p>heparin and ibuprofen both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>icosapent<p>icosapent, heparin.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Icosapent may prolong bleeding time; monitor periodically if coadministered with other drugs that affect bleeding.</p></li><li>imatinib<p>imatinib, heparin.
Either increases toxicity of the other by Other (see comment). Modify Therapy/Monitor Closely. 
Comment: Imatinib may cause thrombocytopenia; bleeding risk increased when imatinib is coadministered with anticoagulants, NSAIDs, platelet inhibitors, and thrombolytic agents; patients requiring anticoagulation while on imatinib should receive LMWH or unfractionated heparin instead of warfarin because of multiple interaction mechanisms of imatinib with warfarin.</p></li><li>indomethacin<p>heparin and indomethacin both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>iodine (radioactive)<p>iodine (radioactive) decreases effects of heparin by pharmacodynamic antagonism. Use Caution/Monitor.</p></li><li>irbesartan<p>heparin increases toxicity of irbesartan by Other (see comment). Use Caution/Monitor. 
Comment: Low molecular weight heparins may suppress adrenal aldosterone secretion, which can potentially cause hyperkalemia.</p></li><li>ketoprofen<p>heparin and ketoprofen both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>ketorolac<p>heparin and ketorolac both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>ketorolac intranasal<p>heparin and ketorolac intranasal both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>lisinopril<p>heparin increases toxicity of lisinopril by Other (see comment). Use Caution/Monitor. 
Comment: Low molecular weight heparins may suppress adrenal aldosterone secretion, which can potentially cause hyperkalemia.</p></li><li>lofepramine<p>lofepramine increases levels of heparin by decreasing metabolism. Use Caution/Monitor.</p></li><li>lornoxicam<p>heparin and lornoxicam both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>losartan<p>heparin increases toxicity of losartan by Other (see comment). Use Caution/Monitor. 
Comment: Low molecular weight heparins may suppress adrenal aldosterone secretion, which can potentially cause hyperkalemia.</p></li><li>meclofenamate<p>heparin and meclofenamate both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>mefenamic acid<p>heparin and mefenamic acid both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>melatonin<p>melatonin increases effects of heparin by anticoagulation. Use Caution/Monitor. Melatonin may decrease prothrombin time.</p></li><li>meloxicam<p>heparin and meloxicam both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>methimazole<p>methimazole decreases effects of heparin by pharmacodynamic antagonism. Use Caution/Monitor.</p></li><li>methylphenidate<p>methylphenidate increases effects of heparin by decreasing metabolism. Use Caution/Monitor.</p></li><li>methylprednisolone<p>methylprednisolone, heparin. Other (see comment). Use Caution/Monitor. 
Comment: Corticosteroids may decrease anticoagulant effects by increasing blood coagulability; conversely, they may impair vascular integrity, thus increasing bleeding risk.  Monitor INR closely.</p></li><li>mipomersen<p>mipomersen, heparin.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: Both drugs have potential to increase hepatic enzymes; monitor LFTs.</p></li><li>mistletoe<p>heparin increases and mistletoe decreases anticoagulation. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.</p></li><li>moexipril<p>heparin increases toxicity of moexipril by Other (see comment). Use Caution/Monitor. 
Comment: Low molecular weight heparins may suppress adrenal aldosterone secretion, which can potentially cause hyperkalemia.</p></li><li>nabumetone<p>heparin and nabumetone both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>naproxen<p>heparin and naproxen both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>nettle<p>heparin increases and nettle decreases anticoagulation. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.</p></li><li>nintedanib<p>nintedanib increases effects of heparin by anticoagulation. Use Caution/Monitor. Nintedanib is a VEGFR inhibitor, and may increase the risk of bleeding; monitor patients on full anticoagulation therapy; monitor closely for bleeding and adjust therapy as needed .</p></li><li>nitroglycerin rectal<p>nitroglycerin rectal decreases effects of heparin by Other (see comment). Use Caution/Monitor. 
Comment: Although an interaction has been reported between IV heparin and nitroglycerin (resulting in a decrease in anticoagulant effect of heparin), the data are not consistent. If patients are to receive IV heparin and nitroglycerin concurrently, the anticoagulation status of the patient must be checked.</p></li><li>olmesartan<p>heparin increases toxicity of olmesartan by Other (see comment). Use Caution/Monitor. 
Comment: Low molecular weight heparins may suppress adrenal aldosterone secretion, which can potentially cause hyperkalemia.</p></li><li>omega 3 carboxylic acids<p>omega 3 carboxylic acids, heparin. Other (see comment). Use Caution/Monitor. 
Comment: Patients taking omega-3 acids and an anticoagulant or other drug affecting coagulation should be monitored periodically due to potential increased risk of bleeding.</p></li><li>omega 3 fatty acids<p>omega 3 fatty acids, heparin. Other (see comment). Use Caution/Monitor. 
Comment: Patients taking omega-3-fatty acids and an anticoagulant or other drug affecting coagulation should be monitored periodically due to potential increased risk of bleeding. .</p></li><li>oxaprozin<p>heparin and oxaprozin both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>panax ginseng<p>heparin and panax ginseng both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>parecoxib<p>heparin and parecoxib both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>pau d'arco<p>heparin and pau d'arco both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>pegaspargase<p>pegaspargase increases effects of heparin by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of bleeding events.</p></li><li>perindopril<p>heparin increases toxicity of perindopril by Other (see comment). Use Caution/Monitor. 
Comment: Low molecular weight heparins may suppress adrenal aldosterone secretion, which can potentially cause hyperkalemia.</p></li><li>phenytoin<p>heparin increases levels of phenytoin by unknown mechanism. Use Caution/Monitor.<span><br><br></span>phenytoin, heparin. Other (see comment). Use Caution/Monitor. 
Comment: Hydantoin anticonvulsants increase anticoagulant effects at first, then decrease those effects with continued use (2+ wks).  There are multiple mechanisms involved, including enzyme induction, plasma protein binding site competition, and additive effects on prothrombin time.</p></li><li>phytoestrogens<p>heparin and phytoestrogens both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>piroxicam<p>heparin and piroxicam both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>porfimer<p>heparin decreases effects of porfimer by pharmacodynamic antagonism. Use Caution/Monitor.</p></li><li>potassium citrate/citric acid<p>heparin and potassium citrate/citric acid both increase  serum potassium. Use Caution/Monitor.</p></li><li>prednisolone<p>prednisolone, heparin. Other (see comment). Use Caution/Monitor. 
Comment: Corticosteroids may decrease anticoagulant effects by increasing blood coagulability; conversely, they may impair vascular integrity, thus increasing bleeding risk.  Monitor INR closely.</p></li><li>prednisone<p>prednisone, heparin. Other (see comment). Use Caution/Monitor. 
Comment: Corticosteroids may decrease anticoagulant effects by increasing blood coagulability; conversely, they may impair vascular integrity, thus increasing bleeding risk.  Monitor INR closely.</p></li><li>propafenone<p>propafenone increases effects of heparin by decreasing metabolism. Use Caution/Monitor.</p></li><li>propylthiouracil<p>propylthiouracil decreases effects of heparin by pharmacodynamic antagonism. Use Caution/Monitor.</p></li><li>quinapril<p>heparin increases toxicity of quinapril by Other (see comment). Use Caution/Monitor. 
Comment: Low molecular weight heparins may suppress adrenal aldosterone secretion, which can potentially cause hyperkalemia.</p></li><li>ramipril<p>heparin increases toxicity of ramipril by Other (see comment). Use Caution/Monitor. 
Comment: Low molecular weight heparins may suppress adrenal aldosterone secretion, which can potentially cause hyperkalemia.</p></li><li>reishi<p>heparin and reishi both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>reteplase<p>heparin and reteplase both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>rifabutin<p>rifabutin decreases levels of heparin by increasing metabolism. Use Caution/Monitor.</p></li><li>rivaroxaban<p>rivaroxaban, heparin.
Either increases effects of the other by anticoagulation. Use Caution/Monitor. Avoid concurrent use of rivaroxaban with other anticoagulants due to increased bleeding risk other than during therapeutic transition periods where patients should be observed closely. Monitor for signs/symptoms of blood loss.</p></li><li>sacubitril/valsartan<p>heparin increases toxicity of sacubitril/valsartan by Other (see comment). Use Caution/Monitor. 
Comment: Heparin may suppress adrenal aldosterone secretion, which can potentially cause hyperkalemia.</p></li><li>salicylates (non-asa)<p>heparin and salicylates (non-asa) both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>salsalate<p>heparin and salsalate both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>saw palmetto<p>saw palmetto increases toxicity of heparin by unspecified interaction mechanism. Use Caution/Monitor. May increase risk of bleeding.</p></li><li>siberian ginseng<p>heparin and siberian ginseng both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>sulfasalazine<p>heparin and sulfasalazine both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>sulindac<p>heparin and sulindac both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>telmisartan<p>heparin increases toxicity of telmisartan by Other (see comment). Use Caution/Monitor. 
Comment: Low molecular weight heparins may suppress adrenal aldosterone secretion, which can potentially cause hyperkalemia.</p></li><li>tenecteplase<p>heparin and tenecteplase both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>ticagrelor<p>ticagrelor, heparin.
Either increases effects of the other by anticoagulation. Use Caution/Monitor. Increased risk of bleeding during concomitant use of medications that increase potential for bleeding.</p></li><li>tipranavir<p>tipranavir increases effects of heparin by pharmacodynamic synergism. Use Caution/Monitor. Tipranavir has mild antiplatelet activity that may incr bleeding risk.</p></li><li>tolfenamic acid<p>heparin and tolfenamic acid both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>tolmetin<p>heparin and tolmetin both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>trandolapril<p>heparin increases toxicity of trandolapril by Other (see comment). Use Caution/Monitor. 
Comment: Low molecular weight heparins may suppress adrenal aldosterone secretion, which can potentially cause hyperkalemia.</p></li><li>triamcinolone<p>triamcinolone, heparin. Other (see comment). Use Caution/Monitor. 
Comment: Corticosteroids may decrease anticoagulant effects by increasing blood coagulability; conversely, they may impair vascular integrity, thus increasing bleeding risk.  Monitor INR closely.</p></li><li>triclofos<p>triclofos increases effects of heparin by unspecified interaction mechanism. Use Caution/Monitor.</p></li><li>valsartan<p>heparin increases toxicity of valsartan by Other (see comment). Use Caution/Monitor. 
Comment: Low molecular weight heparins may suppress adrenal aldosterone secretion, which can potentially cause hyperkalemia.</p></li><li>vorapaxar<p>heparin, vorapaxar.
Either increases effects of the other by anticoagulation. Use Caution/Monitor. Coadministration of anticoagulants, antiplatelets, or other drug affecting coagulation should be monitored periodically due to potential increased risk of bleeding.</p></li><li>vortioxetine<p>heparin, vortioxetine.
Either increases effects of the other by serotonin levels. Use Caution/Monitor.</p></li>